Photo Credit: karenfoleyphotography / Shutterstock.com
The editorial did not kick around the bush. After decades of “expanding opioid use by minimizing the dangers of addiction,” Pharma will now accept the prerogative of taxpayer income to undo what it did andreverse the opioid epidemic, writes the New York Times. Imagine the supervision giving Big Tobacco the taxation dollars to reverse the repairs it did pulling cigarettes and you see how pornographic this is.
The new public-private partnership between Pharma and the NIH (and upheld by both the FDA and DEA) will try ways to residence the opioid predicament such as “nonaddictive painkillers and new treatments for obsession and overdoses.”
Not surprisingly, Pharma likes its reward. J. David Haddox, clamp boss for policy at Purdue Pharma (who creates OxyContin) appreciates the thought of “converting” the opioid marketplace to abuse-deterrent drugs.
But the CEOs of Pharma’s run group, Pharmaceutical Research and Manufacturers of America or PhRMA, and Purdue Pharma do not conclude the Times’ charges.
There is no reason Pharma shouldn’t be concerned in “the long-term solutions” for the opioid predicament writes PhRMA CEO Stephen Ubl, job Pharma operatives “the best minds in science,” in a letter to the Times. Craig Landau, CEO of Purdue, appreciates the “regulatory horizon to incentivize” Pharma to rise post opioid predicament drugs and writes that Pharma can't “abandon… pain patients,” in a minute to the Times.
The NIH partnership is just the latest instance of supervision greasing opioid Pharma’s palms. On the same day in 2013 that the FDA announced new Vicodin restrictions, it authorized hydrocodone bitartrate-based Zohydro with 5 to 10 times the abuse intensity of OxyContin. The next year the FDA authorized Tarrginiq ER while revelation it could means overdoses and euphoria. In 2015, the FDA authorized opioids for children as immature as 11.
In 2016, Obama sealed a Pharma-bought law curtailing DEA powers to umpire vast opioid sales which bent to “deep-pocketed sequence pharmacies such as CVS and Walgreens and drug placement companies like Cardinal Health and McKesson” wrote the New York Times.
Making Money By Hooking People on Opioids
How did Pharma inspire the opioid addiction? By profitable medical groups to change pain condition discipline so that opioids were the first choice for many conditions. (Notice how pain has spin the “fifth critical sign” and medical crew always ask you now “Are you in pain?” We have Pharma to appreciate for that.)
Pharma also fostered the widespread by pulling the long-term use of opioids despite zero studies including the Cochrane Collection showing long-term reserve or effectiveness. Finally, Pharma did it by revelation doctors and patients that opioids aren’t addictive like the together attention Big Tobacco.
A pain guide supported by the American Geriatrics Society and saved by Janssen (which creates Duragesic, Ultram ER and Nucynta) claims that opioids “allow people with ongoing pain to get back to work, run, and play sports,” and says that worries patients may get bending are a “myth.” More than a hundred people a day now die in the U.S. from that myth.
According to investigative reporter John Fauber, half the American Geriatrics Society panel’s experts who revised opioid discipline in 2009 “had financial ties to opioid companies, as paid speakers, consultants or advisers.” What changes did the experts make to the guidelines? “That over-the-counter pain relievers, such as ibuprofen and naproxen, be used frequency and that doctors instead consider prescribing opioids for all patients with assuage to serious pain,” announced the American Geriatrics Society. The University of Wisconsin’s Pain Policy Studies Group perceived $2.5 million from opioid makers, too as the organisation pushed for––any guesses?––looser opioid use guidelines writes Fauber.
Between 1996 and 2002, Purdue Pharma “funded some-more than 20,000 pain-related educational programs by approach sponsorship or financial grants and launched a multifaceted campaign to inspire long-term use of [opioid painkillers] for ongoing non-cancer pain,“ reports Vox Media. Included in the financial warning was financial support to the American Pain Society, the American Academy of Pain Medicine, the Federation of State Medical Boards, the Joint Commission, pain studious groups, and other organizations, writes Vox, which in spin “advocated for some-more assertive marker and diagnosis of pain, generally use of [opioid painkillers].
Last year, the Los Angeles Times unprotected a trove of emails, memos, assembly mins and sales reports from Purdue Pharma revelation that it secretly selling OxyContin as a 12-hour med when they knew it was an eight hour med heading the way to overdoses and addiction.
Pharma has got so many people on opioids, an ad for opioid-related constipation ran during the 2016 Super Bowl.
Addiction Medicine–Playing Both Sides of the Street
In the last decade “addiction medicine” has spin a bang business with distinction margins of over 20 percent. For example, Bain Capital paid $720 million for CRC Health in 2006 and sole it for $1.18 billion to Acadia Healthcare Company Inc. in 2014. Today Acadia boasts 576 behavioral medical comforts with approximately 17,300 beds in 39 states.
Unlike normal “rehab” which de-emphasized medication drugs and promoted abstinence, stream rehab, either private or taxpayer funded, is an unapologetic Pharma craving and distinction center. Pharma has recast obsession as a psychiatric condition and unless costly psychiatric drugs are prescribed, rehab will be not be reimbursed two psychiatrists operative in the margin have told me. This offer raises health caring costs and taxes.
Addiction medicine, is, unsurprisingly, enmeshed with Pharma. The American Society of Addiction Medicine (ASAM) received $47,500 from Pfizer between 2013 and 2016 according to Pfizer reports. It published a consensus statement in the Dec 2011 Journal of Addictive Medicine titled, “Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction,” that was upheld “by an unlimited educational extend to ASAM from Reckitt-Benckiser Pharmaceutics Inc, manufacturer of Subutex and Suboxone.” No conflicts there.
Like the new Pharma/NIH partnership, these Pharma-funded groups also accept the taxation dollars. The program for AAAP’s 25th Annual Meeting interjection 4 supervision for their financial support: the Center for Substance Abuse Treatment, the Substance Abuse Mental Health Services Administration, the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse.
For opioid addiction, these groups pull buprenorpine, marketed as Suboxone, selling for $560 at CVS and $553 at Target for a 30-day supply last year.
Not surprisingly, buprenorpine has its own Pharma selling group. The National Alliance of Advocates for Buprenorphine Treatment (NAABT), which admits it has “received donations from curative companies” says its goal is to “Educate the open about the illness of opioid obsession and the buprenorphine diagnosis option; help revoke the tarnish and taste compared with patients with obsession disorders; and offer as a passage joining patients in need of diagnosis to buprenorphine diagnosis providers.”
Intended to reinstate opioid/heroin addiction, Suboxone is notoriously formidable to quit and has its own abuse potential. Statistics “show pointy increases in buprenorphine seizures by law enforcement, in reports to poison centers, in emergency room visits for the nonmedical use of the drug and in pediatric hospitalizations for random ingestions,” wrote the New York Times.
When Big Tobacco was destitute for fibbing to consumers that its products were conjunction addictive or deadly, it was forced to compensate $206 billion in the 1998 Tobacco Master Settlement Agreement. Provisions embody profitable states, in perpetuity, for some of the medical costs of people with smoking-related illnesses. When Big Pharma caused a identical flay it paid nothing. Worse, it is now receiving millions to “fix” the predicament it started by selling even some-more drugs.
Martha Rosenberg is an inquisitive health contributor and the author of “Born With a Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp the Public Health (Random House).”